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Abstract
Background: In response to growing recognition of the value of prospective registration of systematic review protocols, we
planned to develop a web-based open access international register. In order for the register to fulfil its aims of reducing
unplanned duplication, reducing publication bias, and providing greater transparency, it was important to ensure the
appropriate data were collected. We therefore undertook a consultation process with experts in the field to identify a
minimum dataset for registration.
Methods and Findings: A two-round electronic modified Delphi survey design was used. The international panel surveyed
included experts from areas relevant to systematic review including commissioners, clinical and academic researchers,
methodologists, statisticians, information specialists, journal editors and users of systematic reviews. Direct invitations to
participate were sent out to 315 people in the first round and 322 in the second round. Responses to an open invitation to
participate were collected separately. There were 194 (143 invited and 51 open) respondents with a 100% completion rate
in the first round and 209 (169 invited and 40 open) respondents with a 91% completion rate in the second round. In the
second round, 113 (54%) of the participants reported having previously taken part in the first round. Participants were asked
to indicate whether a series of potential items should be designated as optional or required registration items, or should not
be included in the register. After the second round, a 70% or greater agreement was reached on the designation of 30 of 36
items.
Conclusions: The results of the Delphi exercise have established a dataset of 22 required items for the prospective
registration of systematic reviews, and 18 optional items. The dataset captures the key attributes of review design as well as
the administrative details necessary for registration.
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Introduction
A protocol should be an integral part of a systematic review, and
is important because it pre-specifies the objectives and methods to
be used. Having a protocol can help restrict the likelihood of
biased post hoc decisions in review methods, such as selective
outcome reporting (because it specifies outcomes of primary
interest, how information about those outcomes will be extracted,
and the methods that might be used to summarize the outcome
data quantitatively). An examination of 47 Cochrane reviews
revealed indirect evidence for possible selective reporting bias for
systematic reviews. Almost all (n = 43) contained a major change,
such as the addition or deletion of outcomes, between the protocol
and the full publication [1]. However, whether (or to what extent)
the changes reflected bias, as opposed to unreported but legitimate
changes in methods as the review methods were developed, was
not clear. For example, the protocol might have aimed to include
specific outcomes, which were then found to be absent from all of
the included studies, leading the reviewers to remove these
outcomes from their final review. Similarly, setting out inclusion
and exclusion criteria prior to author knowledge of the available
studies reduces the potential for selective inclusion based on study
findings. Publication of a protocol additionally promotes trans-
parency of methods and, as it facilitates identification of reviews
that are in process, reduces the potential for unplanned
duplication and allows public review of the planned methods.
Capturing the key elements of a systematic review at the
protocol stage (or at the design stage if there is no formal protocol)
and making these publicly available has similar utility to producing
and publishing systematic review protocols. Additionally, a register
providing a single point of access should be of great benefit in
avoiding unplanned duplication of effort. The issuing of a unique
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identifier linked to a permanent registration record allows
comparison of final reports of reviews with what was planned at
registration.
Support for prospective registration of systematic review
protocols has been gathering momentum, reflected in a number
of recent publications [2,3,4,5]. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that
evaluate healthcare interventions advocates registration and the
PRISMA 2009 Checklist requires protocol registration details, if
available, to include a registration number and details of the
existence of and access to the protocol [2,3].
Until now there has been no widely adopted process to register
systematic reviews formally, outside of specific collections of
reviews, such as those produced by the Cochrane Collaboration.
Recognising the need for registration, the Centre for Reviews and
Dissemination (CRD), in collaboration with an international
Register Advisory Group, took the initiative in establishing
PROSPERO, an international prospective register of systematic
reviews with health outcomes that is freely accessible online (www.
crd.york.ac.uk/PROSPERO).
The aim of PROSPERO is to prospectively register systematic
reviews at the protocol stage; capturing the key attributes of the
protocol or plan; maintaining an audit trail of any subsequent
protocol amendments; and adding details of final publications,
including peer-reviewed articles, and other documents as they
become available. This will provide a permanent public record
and unbiased listing of registered reviews. PROSPERO can
therefore assist in planning new reviews and updating existing ones
by providing stakeholders with information about reviews already
in the pipeline. This should help to reduce unplanned duplication
of effort and to optimise often limited use of research funds.
It will also provide transparency of process, and facilitate
comparison between planned methods and reported results
enabling readers to make judgements about the importance of
any discrepancies [6]. Ultimately this may serve to discourage bias
in the conduct and reporting of reviews.
To achieve these aims, the register needs to capture and make
available relevant information related to potential for bias in a
timely, transparent, and accessible way. At the same time it
should be user friendly and not overly burdensome for those
completing the registration details. It also needs to be able to
accommodate methodological variations between different types
of systematic reviews. The development team recognised that
support for and use of the register would require the involvement
of a range of interested parties including, for example, clinical
and academic researchers, commissioners and journal editors. An
international consultation was therefore undertaken with the
primary objective of establishing the minimum dataset required
for registration of systematic reviews at the protocol stage. A
secondary objective was to raise awareness of the development of
the register.
Methods
The international Register Advisory Group consists of a small
number of key individuals recruited by CRD to assist in taking
forward the development of the register. The advisory group
members collectively have a wide range of systematic review
experience with a variety of methodological interests and
significant statistical expertise. In addition members have a
detailed knowledge of the Cochrane Collaboration approach to
registration of review protocols; experience of clinical trials
registers and authorship of the PRISMA statement. The advisory
group proposed the use of a Delphi exercise to establish the
minimum dataset and subsequently guided each stage of the
process.
Design
A modified Delphi exercise was carried out to obtain opinions
from international experts in the field of systematic review about
which individual constituents of a review protocol should be
included in a registration record. The Delphi technique is a
method of collecting in a structured and iterative way, the
anonymous, individual opinions of a panel with relevant expertise
in the topic where a consensus is required. The basic principle is
for the panel to receive successive questionnaires, each one
containing the anonymous responses to the previous round, and
for them to modify their responses until a consensus is reached
[7,8,9]. We modified the basic Delphi technique for practical
reasons.
The survey population of interest had a high level of Internet
and email access, were likely to be familiar with the use of
electronic online submission processes and to use email as the
principal mode of communication. We aimed to include wide
international participation, minimise cost, and ensure accurate
and efficient collection and analysis of responses. The question-
naires were therefore administered electronically using on-line
survey software Survey Monkey (www.surveymonkey.com).
Participants
The opinions of international experts in health and social care
involved in undertaking, commissioning, or developing methods
for systematic reviews, or in guideline development, were sought,
as were those of healthcare journal editors.
Two lists of participants were prepared; a core panel of
individuals, and an ‘open list’ of organisations, groups, and
electronic mailing lists. The initial circulation list for the core panel
contained 350 names. These individuals were nominated by
members of the register Advisory Group or identified through
existing networks (e.g., the PRISMA Group, the International
Network of Agencies for Health Technology Assessment; and
International Committee of Medical Journal Editors). Email
addresses were collected from personal contact lists and publicly
available sources (e.g., organisational websites). All emails were
personalised to individuals.
The open list included groups such as Guidelines International
Network and the Health Technology Assessment International
Information Resources Group, for onward dissemination to their
members and electronic mailing lists (e.g., Cochrane Methods
Groups and the Coordinating Editors of Cochrane Review
Groups; LIS-MEDICAL and EVIDENCE-BASED-HEALTH,
and World Association of Medical Editors). The open invitation
was also posted on websites (e.g., CRD, National Institute for
Health Research (NIHR), Cochrane Collaboration, Committee on
Publication Ethics) and placed in newsletters (e.g., CRD,
Cochrane Collaboration, NIHR). Details of the exercise were
published in a Lancet comment paper, which directed readers to
the CRD website for further information. This appeared in the e-
version of the Lancet during the survey [10] and in the print
version at a later date [11].
Separate response collectors were used within Survey Monkey
for the two different types of invitation. Anyone responding on a
link cascaded by a core panellist would have been included in the
core panel collector.
The second round was sent to everyone in the core panel again,
including non-responders unless they had requested removal from
the list. In addition those from the open list who completed the
first round and supplied their email addresses were added to the
Consultation on Dataset for Protocol Registration
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revised core panel list. Again, separate collectors were used for the
core panel and open lists. The second (final) round of the survey
required participants to indicate whether they had taken part in
the first round. It was accompanied by a summary report on the
responses to the first round (available from http://www.york.ac.
uk/inst/crd/projects/register.htm).
All responses were anonymous; it was not possible to tell who
responded or to link names to responses even when individuals
informed us they had responded. It was hoped that this would
encourage participation in both rounds and expression of personal
opinion, rather than conforming to group opinion or dropping out
after the first round [9].
In order to assess representation of different stakeholder groups
and identify any differences in the responses between them, simple
demographic details were requested in each questionnaire. These
were designation; membership of organisations; health area of
interest; review method of interest; number of systematic reviews
authored; number of systematic reviews in which involved other
than as author; proportion of work that relates to methodology;
country; and English as a first language.
Instrumentation
The exercise was limited to two rounds, although provision had
been made for subsequent rounds if these were judged necessary
by the register Advisory Group. The questionnaires were piloted
before distribution.
The time in which the questionnaires were ‘open’ for responses
was limited to two weeks for each round. Reminder emails were
sent to all members of the core panel approximately one week
before the close of each round.
A mixture of ‘pick lists’, pre-specified response options, and free
text responses were used to facilitate ease of response and analysis
of data from a wide consultation, with large numbers from diverse
groups, many of whom may not have English as their first
language. In order to ensure that sufficient data were collected and
that key areas addressed fully, ‘pick list’ questions were made
mandatory. That is respondents had to make a choice before they
could submit their answers. It was not mandatory to put anything
into the free text boxes.
The questionnaires were prepared by CRD with advice from
the register Advisory Group. None of those involved in designing,
administering or advising on the questionnaires completed the
survey.
The focus for the questions, the language, and explanations
used were informed by lessons learned from the development of
trials registers, and in particular the requirements for registers as
set out by the WHO trials register platform (http://www.who.int/
ictrp/en/) [12].
Question formulation
A pragmatic decision was taken not to approach panellists in
advance to ask for their participation. This was to minimise the
burden on named individuals who were likely to have limited time
to devote to the process. For the same reason, we drew up a list of
candidate items for inclusion in the minimum data set based on
established guidance for writing systematic review protocols
[13,14,15,16], the PRISMA statement [3] and information from
the WHO trials registry (http://www.who.int/ictrp/en/).
The first round questionnaire sought preferences for 41
candidate items as to whether they should be included in the
minimum data set. Respondents were asked to indicate whether
they thought each item was ‘Essential’, ‘Desirable’ or ‘Not
necessary’. The focus for responses was on the inclusion of data
that would help identify ongoing reviews and enable assessment of
bias when the review was completed. Opinions on the scope of the
register, allocation of unique ID; timing of registration, dealing
with amendments to protocols, publications, and updating of
reviews, and existence of other protocol registers were also sought.
However, these items relating to the development and implemen-
tation of a register are not presented in detail here, but are
included in the summary reports, available at http://www.york.ac.
uk/inst/crd/projects/register.htm.
The second round questionnaire set out suggestions for which
items should be mandatory and which should be optional, based
on the register Advisory Group’s interpretation of the first round
responses. Participants were asked to ‘Agree’, or ‘Disagree’ with
the suggested categorisation, to state that an item was ‘Not needed’
or state that they had ‘No opinion’. If they disagreed with a
categorisation, they were asked to indicate the direction of the
disagreement, e.g., that an item suggested as compulsory should be
down-weighted to optional. Again the focus for responses was to
identify the minimum dataset to achieve the aims of registration.
As with the first round questionnaire, free text boxes for comments
and suggestions were provided but not mandatory.
The majority vote for ‘Essential’ or ‘Desirable’ in the first round
was used to categorise fields as ‘Required’ or ‘Optional’,
respectively for the second round questionnaire.
Analysis
All responses were collated in ‘Survey Monkey’ for tabulation
and analysis. A summary report on each round was compiled and
circulated to both distribution lists (available from http://www.
york.ac.uk/inst/crd/projects/register.htm).
Where possible, decisions were based on achieving consensus at
a designated level of 70% agreement. This level of consensus was
agreed by the Advisory Group as being greater than two-thirds of
opinion, indicating a clear majority. Other decisions were made
taking into consideration the distribution of alternative responses.
Ethical approval
Formal written consent was not sought; submission of
completed questionnaires was taken as implied consent. The
research was approved by the University of York Humanities and
Social Sciences Ethics Committee (HSSEC 12-2009/10).
Results
Responses and respondents
The first round core panel list included 327 direct invitations, 12
were excluded as their emails were returned as undelivered,
making the initial list 315. Five people declined to take part and
were removed from the mailing list.
The second round core panel list included 322 direct invitations,
four were excluded (three emails were returned as undelivered and
one was known to be unavailable while the survey was open),
making the list 318. One declined to take part and was removed
from the mailing list.
A separate collector was set up for the open list invitation to
participate. Both the first and second round questionnaires were
sent to a general contact at 15 different organisations, and to a
named contact for internal circulation in five other organisations
or groups.
There were 194 (143 invited and 51 open) respondents with a
100% completion rate in the first round and 209 (169 invited and
40 open) respondents with a 91% completion rate in the second
round. Of those who took part in the second round, 113 (54%)
said they had taken part in the first round; 72 (34%) said they had
not; and 24 (12%) could not remember (Table 1). A comparison of
Consultation on Dataset for Protocol Registration
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responses to the second round questionnaire showed no significant
differences between those taking part in both rounds and those
only taking part in the second round.
There were no significant differences between role designations
(Table S1); areas of health interest (Table S2); review methods of
interest (Table S3); authorship of (Table S4), or involvement in
systematic reviews (Table S5); or proportion of work related to
research methodology (Table S6); between the first and second
round respondents.
There was little difference between the responses of those who
were members of The Cochrane Collaboration and those who
were not. There were three items in round one and two items in
round two where the differences were of statistical significance.
After Bonferroni adjustment for multiple comparisons, these were
no longer statistically significant (Table S7).
In the first round, 128 (66%) respondents said English was their
first language. In the second round, English was the first language
for 124 (65%) of respondents. Respondents to both the first and
second rounds were based in 34 countries, with an additional six
countries represented in the first round only, and a different five
countries represented in the second round only (Figure S1).
In the second round we specifically asked participants whether
they supported the principle of registration of ongoing systematic
reviews; 199 (95.2%) of participants said they did; three (1.4%) did
not and seven (3.3%) had no opinion.
Minimum dataset
Following review of the first round responses, it was decided that
the Anticipated publication date field would not be included in the
second round. This was because of the large number of comments
requesting that the list of items be kept as small as possible, and
158 (82%) respondents felt this field should be optional or was not
necessary. The field would be difficult for researchers to estimate
at the protocol stage and its inclusion in the register was not
integral to achieving the stated aims.
Likewise, 121 (63%) respondents felt it was ‘‘Desirable’’ or ‘‘Not
necessary’’ to include the Economic Evaluations field. As this
information could and should be included in the Review Question
field and elsewhere, it was not included in the second round
questionnaire.
Taking into account first round feedback on the need to keep
the dataset to the minimum and focus on information that would
contribute to reducing bias, it was proposed that although the
majority of respondents felt that the Context and Data extraction
fields should be required fields, they should be included as optional
fields. None of the fields in the first round had a majority in favour
of ‘Not needed’.
In the first round of questions, primary and secondary outcomes
were presented as separate items from effect measures in order to
find out if participants felt both were needed. As only 9% and 12%
of the respondents, (respectively for primary and secondary
outcomes), felt that effect measures were not necessary, these
fields were combined for the second round (Table 2). Time points
were added as a requirement in response to suggestions from
participants.
Informed by the responses to the Delphi exercise, the register
Advisory Group confirmed that all items with 70% or greater
agreement would be included as Required or Optional fields as
responses indicated.
In round one, there was $70% agreement on 14 of 40 items;
60–69% agreement on 7 items; 50–59% agreement on 8 items;
40–49% agreement on 10 items and 30–39% on one item.
After the second round, a 70% or greater agreement was
reached on whether 30 of 36 items should be required or optional.
There was 60–69% agreement on two and 50–59% agreement on
the remaining four items (Table 2).
The final PROSPERO dataset agreed by the register Advisory
Group consists of 40 items, 22 of which are required, and the
remainder are optional. Of the required fields, 12 are for details of
review methods, 10 are related to the review title, timescale and
review team (Table 3). In addition, the unique identification
number was designated as part of the dataset by the Advisory
Group as PROSPERO creates a unique number for each
accepted registration record.
Discussion
Although the drivers for trials registration differ in some respects
(e.g., legal ethical requirement [17]), systematic review protocol
registration faces the same potential barriers as trials registration.
In order to avoid the problems arising from the existence of
multiple trials registers [18,19] by providing a free, single,
comprehensive, open access register, a balance between level of
detail required and utility was sought. The proposed level of
information to be entered for each field was included in the survey
as the quality of data recorded in trials registers has been found to
vary considerably [20,21].
The aims of registering a systematic review include the
provision of sufficient information to (i) determine whether
reviews already in the pipeline might negate the need to initiate
a new review, (ii) enhance the transparency and completeness of
the plans for the systematic review, and (iii) make informed
judgements about potential risk of bias. The objective of this
Delphi process was to establish the minimum data set that will
achieve these three aims. The Delphi process did not seek to
capture the attributes of the wider information that should be
included in a full protocol for a systematic review, or to
determine all the variables that people might wish to record in
registers of systematic reviews that would be used for other
purposes.
The Delphi technique was chosen for its flexibility and
adaptability in gathering and analysing the necessary data, and
in particular for the utility of the process in garnering views and
opinions from a broad spectrum of people [8]. The commission-
ing, undertaking, publishing and use of systematic reviews involves
diverse disciplines, each with their own particular perspective, with
both inter- and intra-disciplinary differences of opinion. For the
Table 1. Number of responses to questionnaires.
Number on
core panel list
Number who
started the survey
Core panel
collector Open collector
Number who completed
the survey (%)
First round 315 194 143 51 194 (100)
Second round 318 209 169 40 190 (91)
doi:10.1371/journal.pone.0027319.t001
Consultation on Dataset for Protocol Registration
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27319
Table 2. Registration dataset response rates for Delphi round one and two.
Field title Delphi first round responses (194) Delphi second round responses (209)
Essential Desirable
Not
necessary
Agree should
be Required*/
Optional
Disagree should
be Optional/
Required*
Disagree,
not needed
No
opinion
1 Review title 174 (90%) 17 (9%) 3 (2%) 189 (98%)* 4 (2%) 0 (0%) 0 (0%)
2 Named contact 186 (96%) 5 (3%) 3 (2%) 187 (97%)* 5 (3%) 0 (0%) 1 (1%)
3 Organisational affiliation of the review 136 (70%) 51 (26%) 7 (4%) 162 (84%)* 23 (12%) 1 (1%) 7 (4%)
4 Named contact address 74 (38%) 91 (47%) 29 (15%) 148 (77%) 30 (16%)* 9 (5%) 6 (3%)
5 Named contact phone number Item not included in first round 151 (78%) 13 (7%)* 21 (11%) 8 (4%)
6 Named contact email 166 (86%) 26 (13%) 2 (1%) 180 (93%)* 11 (6%) 0 (0%) 2 (1%)
7 Review team 76 (39%) 82 (42%) 36 (19%) 129 (67%) 49 (25%)* 10 (5%) 5 (3%)
8 Review team members’
rsorganisational affiliations
48 (25%) 104 (54%) 42 (22%) 146 (76%) 27(14%)* 12 (6%) 8 (4%)
9 Collaborators 35 (18%) 106 (55%) 53 (27%) 147 (76%) 18 (9%)* 19 (10%) 9 (5%)
10 Anticipated or actual start date 125 (64%) 57 (29%) 12 (6%) 170 (89%)* 18 (9%) 1 (1%) 3 (2%)
11 Anticipated completion date 91 (47%) 88 (45%) 15 (8%) 152 (79%)* 33 (17%) 3 (2%) 4 (2%)
12 Anticipated publication date 36 (19%) 109 (56%) 49 (25%) Item not included in second round
13 Funding sources/sponsors 155 (80%) 31 (16%) 8 (4%) 179 (93%)* 12 (6%) 1 (1%) 0 (0%)
14 Conflicts of interest 152 (78%) 31 (16%) 11 (6%) 173 (90%)* 14 (7%) 3 (2%) 2 (1%)
15 Other registration details Item not included in first round 134 (70%) 50 (26%)* 8 (4%) 0 (0%)
16 Organisation reference number 55 (28%) 88 (45%) 51 (26%) 139 (72%) 17 (9%)* 18 (9%) 18 (9%)
17 Language 110 (57%) 65 (34%) 19 (10%) 103 (54%) 72 (38%)* 10 (5%) 7 (4%)
18 Country 67 (35%) 83 (43%) 44 (23%) 136 (71%) 33 (17%)* 17 (9%) 6 (3%)
19 Key words 133 (69%) 47 (24%) 14 (7%) 114 (59%) 69 (36%)* 6 (3%) 3 (2%)
20 Any other information 30 (16%) 101 (52%) 63 (33%) 170 (89%) 6 (3%)* 8 (4%) 8 (4%)
21 Review question(s) 186 (96%) 6 (3%) 2 (1%) 186 (97%)* 4 (2%) 1 (1%) 0 (0%)
22 Economic Evaluations 73 (38%) 85 (44%) 36 (19%) Item not included in second round
23 Searches 131 (68%) 42 (22%) 21 (11%) 155 (81%)* 32 (17%) 3 (2%) 1 (1%)
24 URL to search strategy 51 (26%) 93 (48%) 50 (26%) 143 (75%) 28 (15%)* 14 (7%) 6 (3%)
25 Types of study to be included 167 (86%) 23 (12%) 4 (2%) 167 (87%) 21 (11%) 3 (2%) 0 (0%)
26 Condition or domain being studied 150 (77%) 35 (18%) 9 (5%) 177 (93%) 11 (6%) 3 (2%) 0 (0%)
27 Participants/population 176 (91%) 14 (7%) 4 (2%) 178 (93%) 12 (6%) 1 (1%) 0 (0%)
28 Intervention(s), exposure(s) 176 (91%) 15 (8%) 3 (2%) 184 (96%) 6 (3%) 1 (1%) 0 (0%)
29 Comparator(s)/control 168 (87%) 24 (12%) 2 (1%) 180 (94%) 9 (5%) 1 (1%) 1 (1%)
30 Contexta 99 (51%) 77 (40%) 18 (9%) 106 (56%) 77 (40%) 3 (2%) 5 (3%)
31 Primary outcome(s) 180 (93%) 13 (7%) 1 (1%) 177 (93%) 11 (6%) 3 (2%) 0 (0%)
32 Effect measures for primary outcome(s) 126 (65%) 51 (26%) 17 (9%) (Merged with item 31)
33 Secondary outcome(s) 130 (67%) 55 (28%) 9 (5%) 146 (76%) 38 (20%) 5 (3%) 2 (1%)
34 Effect measures for secondary outcome(s) 82 (42%) 88 (45%) 24 (12%) (Merged with item 33)
35 Data extraction, (selection and coding)a 100 (52%) 58 (30%) 36 (19%) 102(53%) 76 (40%) 11 (6%) 2 (1%)
36 Risk of bias (quality) assessment 118 (61%) 54 (28%) 22 (11%) 142 (74%) 35 (18%) 11 (6%) 3 (2%)
37 Strategy for data synthesis 131 (68%) 46 (24%) 17 (9%) 136 (71%) 41(22%) 10 (5%) 4 (2%)
38 Methods for exploring heterogeneity 1b 93 (48%) 67 (35%) 34 (18%) (Merged with 35 and 36 into item 37)
39 Methods for exploring heterogeneity 2c 78 (40%) 76 (40%) 40 (20%) (Merged with 34 and 36 into item 37)
40 Definition and rationale for use
of specific techniques
73 (38%) 71 (37%) 50 (26%) (Merged with 34 and 35 into item 37)
41 Analysis of subgroups or subsets (Presented in items 34, 35, 36 in first round)134 (70%) 42 (22%) 10 (5%) 5 (3%)
42 Dissemination plans 35 (18%) 98 (51%) 61 (31%) 151 (79%) 10 (5%) 24 (13%) 6 (3%)
43 Details of any existing review of the
same topic by the same authors
139 (72%) 39 (20%) 16 (8%) 124 (65%) 54 (28%) 8 (4%) 5 (3%)
aThe majority of respondents in round one selected this as ‘essential’.
bHow heterogeneity will be explored. Under what circumstances will a meta-analysis be considered appropriate.
cCovariates to be explored with method of analysis.
doi:10.1371/journal.pone.0027319.t002
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Table 3. PROSPERO dataset.
Review title and timescale
1 Review title* The working title of the review.
2 Original language title The working title in the language of the review where this is not English.
3 Anticipated or actual start date* The date when the systematic review commenced, or is expected to commence.
4 Anticipated completion date* The date by which the review is expected to be completed.
5 Stage of review at time of registration* The stage of progress of the review at the time of initial registration.
Review team details
6 Named contact* The named contact acts as the guarantor for the accuracy of the information presented
in the Register record.
7 Named contact email* The electronic mail address of the named contact.
8 Named contact address The full postal address for the named contact.
9 Named contact phone number The telephone number for the named contact, including international dialling code.
10 Review team members and their organisational affiliations Names of all members of the review team and their organisational affiliations.
11 Organisational affiliation of the review* Details of the organisational affiliations for this review.
12 Funding sources/sponsors* Details of the individuals, organizations, groups or other legal entities who take
responsibility for initiating, managing, sponsoring and/or financing the review.
13 Conflicts of interest* Any conditions that could lead to actual or perceived undue influence on judgements
concerning the main topic investigated in the review.
14 Collaborators The name, affiliation and role of any individuals or organisations who are working on
the review but who are not listed as review team members.
Review methods
15 Review question(s)* The question(s) to be addressed by the review.
16 Searches* Details of the sources to be searched, and any restrictions (e.g. language or publication
period).
17 URL to search strategy A link to the search strategy or an example of a search strategy for a specific database.
18 Condition or domain being studied* A short description of the disease, condition or healthcare domain being studied,
including health and wellbeing outcomes.
19 Participants/population* Summary criteria for the participants or populations being studied by the review. The
preferred format includes details of both inclusion and exclusion criteria.
20 Intervention(s)/exposure(s)* Full and clear descriptions of the nature of the interventions or the exposures to be
reviewed.
21 Comparator(s)/control* Details of the alternatives against which the main subject/topic of the review will be
compared.
22 Types of study to be included initially* Details of the study designs to be included in the review. If there are no restrictions on
the types of study design eligible for inclusion, this should be stated.
23 Context Summary details of the setting and other relevant characteristics which help define the
inclusion or exclusion criteria.
24 Primary outcome(s)* The most important outcomes, including information on timing and effect measures,
as appropriate.
25 Secondary outcomes* Any additional outcomes that will be addressed, including information on timing and
effect measures, as appropriate.
26 Data extraction (selection and coding) The procedure for selecting studies for the review and extracting data, including the
number of researchers involved and how discrepancies will be resolved.
27 Risk of bias (quality) assessment* Whether and how risk of bias will be assessed, how the quality of individual studies will
be assessed, and whether and how this will influence the planned synthesis.
28 Strategy for data synthesis* The planned general approach to be used, for example whether the data to be used
will be aggregate or at the level of individual participants, and whether a quantitative
or narrative (descriptive) synthesis is planned.
29 Analysis of subgroups or subsets* Any planned exploration of subgroups or subsets within the review. ‘None planned’ is a
valid response if no subgroup analyses are planned.
General information
30 Type of review The type of review.
31 Language The language(s) in which the review is being written and will be made available.
32 Country The country or countries in which the review is being carried out.
33 Other registration details Other places where the systematic review is registered (such as with The Cochrane
Collaboration, The Campbell Collaboration, or The Joanna Briggs Institute).
34 Reference and/or URL for published protocol The citation and link for the published protocol, if there is one.
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register to fulfil its aims and cater for all potential users it was
important to ensure that experts from all the relevant disciplines be
invited to contribute their opinions in order to reach a consensus.
It would not have been possible to arrange face to face meetings
with the number of participants achieved by this approach. The
Delphi approach allowed us to carry out the consultation with
complete anonymity and maintain a broad heterogeneity in
participants without any one discipline or individual having more
influence than another.
For pragmatic reasons we modified the standard Delphi
technique, and discuss here the limitations of the methods we used.
The notion of an ‘international expert’ in the defined areas is
largely subjective. We hoped to minimise any inadvertent bias in
the selection of the core panel by also issuing an open invitation to
participate. However, because of the option of sharing email
invitations, we cannot be sure that only core panel members
responded to the core panel collector. Nonetheless, a comparison
of the data from the two collectors showed little variation in
response between the two groups.
Ideally, the same participants should respond to each round of a
Delphi process. The pragmatic decision not to approach
participants in advance to confirm commitment to the whole
exercise, was balanced against the number being invited to take
part. Just over half the respondents participated in both rounds. A
comparison of second round responses between returning
respondents and new participants showed no significant differenc-
es. It is unlikely therefore that the approach taken introduced
additional bias.
Normally the first round of a Delphi would present open
questions such as ‘What items do you think should be included in the
registration of systematic reviews at the protocol stage?’ However, given that
the items that should be included in a systematic review protocol
are already well established and to reduce the burden on
participants, we invited the first round respondents to comment
on the utility of a pre-prepared list of candidate items.
Respondents also had the opportunity to suggest additional items.
The suggestions that were received and adopted were: the addition
of an optional field to record other registration details (e.g., on The
Cochrane Library); the requirement of time points to be included
in the primary and secondary outcomes fields; and an optional
field for telephone contact details.
Based on 315 invitations to participate in the first round, and
143 respondents, the response rate was 45%. In the second round
318 invitations were sent out and 169 responses received, making
the response rate 54%. However, the true response rates may be
lower as we cannot know how many individuals received a
cascaded invitation.
Our decision not to use a pre-determined list of participants for
the two rounds was based on the desire to ensure a range of
respondents, but could have led to an unrepresentative sample of
participants. In the event, responses were received from all key
groups and those people who labelled themselves as researchers/
reviewers were divided similarly in each round between members
(119 round one; 105 round two) and non-members (75 round one;
81 round two) of The Cochrane Collaboration.
We succeeded in gathering the opinions and judgments of a
large and diverse range of relevant experts. Given the heteroge-
neity of the respondents and their interests, we believe that the
degree of consensus achieved is acceptable, but we will keep the list
of data items under review and will revisit it after it has been in use
for a year, as part of a wider evaluation of the utility of
PROSPERO.
Conclusion
The consultation revealed widespread support for the principle
of registration of systematic reviews, and the Delphi exercise
established a dataset of 22 required items for the prospective
registration of systematic reviews, and 18 optional items. The
dataset captures the key attributes of review design, as well as the
administrative details necessary for registration. The findings were
also used to inform the development and implementation of the
technical and process elements of PROSPERO.
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